HCRN-GI23-643, titled, “Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer,” will be presented as a Trials in Progress poster at the American Society of Clinical Oncology® (ASCO) Gastrointestinal Cancers Symposium 2025 in San Francisco. This study is led by Ibrahim Sahin, MD, of UPMC Hillman Cancer Center.

• Session Title: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
• Presentation Title: Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01
• Poser Bd #: M21
• Date: January 25 from 7:00 a.m. – 7:55 a.m. PST

This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.

See abstract: https://meetings.asco.org/abstracts-presentations/241991

Learn more: https://hoosiercancer.org/clinical-trials/trial/hcrn-gi23-643/

About Hoosier Cancer Research Network:
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants in have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.